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Abstract
Background: Nesiritide is indicated in the treatment of acute decompensated heart failure.
However, a recent meta-analysis reported that nesiritide may be associated with an increased risk
of death. Our goal was to evaluate the impact of nesiritide treatment on four outcomes among
adults hospitalized for congestive heart failure (CHF) during a three-year period.
Methods: CHF patients discharged between 1/1/2002 and 12/31/2004 from the Adventist Health
System, a national, not-for-profit hospital system, were identified. 25,330 records were included in
this retrospective study. Nesiritide odds ratios (OR) were adjusted for various factors including
nine medications and/or an APR-DRG severity score.
Results: Initially, treatment with nesiritide was found to be associated with a 59% higher odds of
hospital mortality (Unadjusted OR = 1.59, 95% confidence interval [CI]: 1.31–1.93). Adjusting for
race, low economic status, APR-DRG severity of illness score, and the receipt of nine medications
yielded a nonsignificant nesiritide OR of 1.07 for hospital death (95% CI: 0.85–1.35). Nesiritide was
positively associated with the odds of prolonged length of stay (all adjusted ORs = 1.66) and
elevated pharmacy cost (all adjusted ORs > 5).
Conclusion: In this observational study, nesiritide therapy was associated with increased length
of stay and pharmacy cost, but not hospital mortality. Randomized trials are urgently needed to
better define the efficacy, if any, of nesiritide in the treatment of decompensated heart failure.
Background
Congestive heart failure (CHF) is a significant public
health concern and pressing public policy issue. With
greater than 5 million patients who carry the diagnosis of
CHF in the United States alone, and with approximately
550,000 new cases per year, it is no surprise that acute
decompensated heart failure (ADHF) is the leading cause
of hospitalization in the U.S. in persons over the age of 65
years [1,2]. Hospital discharges for CHF rose from
377,000 in 1979 to 970,000 in 2002, an increase of 157%.
In 2005 it is estimated that $27.9 billion will be spent on
direct costs for CHF, $14.7 billion on hospital care, and
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$2.9 billion on drugs/other medical durables [1]. With
hospital readmission rates as high as 50% at six months,
and with the major medical society guidelines focused on
the outpatient management of CHF, physicians are always
looking for innovative approaches as well as guidance on
how to best manage patients with ADHF [3-5].
In 2001 nesiritide (Natrecor®) was approved by the FDA
for the intravenous treatment of patients with ADHF who
have dyspnea at rest or with minimal activity, based on
data which showed nesiritide reduced pulmonary capil-
lary wedge pressure and improved dyspnea [6]. Given the
plausible biological mechanism of action of nesiritide
and its safety profile as compared to existing intravenous
inotropic agents, nesiritide use rapidly increased [7-9].
However, two recent publications have questioned the
safety of nesiritide in terms of increased mortality and
worsening renal function in patients treated with this drug
for acutely decompensated heart failure [10,11]. At one
point physicians at the Cleveland Clinic, one of the
nation's largest cardiac centers, considered severely cur-
tailing or even banning the clinic's use of nesiritide [12].
Subsequently, a panel of cardiologists and heart failure
experts was convened, chaired by Dr. Eugene Braunwald,
to review the data associated with nesiritide and made rec-
ommendations on its use. Reviewing the published data
along with other information available on nesiritide, the
panel recommended strictly limiting the use of nesiritide
to patients presenting to the hospital with ADHF who
have dyspnea at rest, and recommend continued enroll-
ment in ongoing trials of nesiritide, as well as pro-active
educational programs to inform physicians regarding con-
ditions and circumstances in which nesiritide should and
should not be used [13].
Adventist Health System (AHS) is a multi-hospital, not-
for-profit, health care system with community hospitals
in many geographic locations. It has over 8,000 admis-
sions per year for CHF. Given the volume of patients seen
for CHF and the exponential growth in the use of nesir-
itide at our facilities, we decided to review our data over a
three year period (2002 to 2004; representing more than
25,000 patient encounters) looking specifically at both
the clinical outcomes and financial impact of nesiritide
use.
Methods
Patient Population
Data from 31 of the AHS hospitals were electronically
transferred to a clinical decision support software vendor
MEDai (Medical Artificial Intelligence, Inc., Orlando,
Florida). Discharge diagnoses were coded using the Inter-
national Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM).
Our study included electronic records of patients who
were 18 years of age or older who were discharged for CHF
between January 1, 2002, and December 31, 2004. CHF
was defined as the occurrence of one of the following
ICD-9-CM codes in the primary diagnosis field: 402.01,
402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, 428.0, 428.1, 428.9.
Records were excluded if they had missing values for the
dependent or independent variables under study. A total
of 25,330 records were included in this study. These
records do not represent 25,330 unique patients since
some patients were readmitted during the study period for
CHF. This sample included 18,298 distinct patients.
Primary Statistical Analysis
The exposure of interest was receipt of nesiritide during
the hospital stay: Patients who received nesiritide were
compared to patients who did not receive nesiritide. Four
outcomes were studied: hospital mortality, prolonged
length of stay (defined below), elevated pharmacy cost
(defined below), and readmission to an AHS hospital
within 31 days for a Diagnosis Related Group (DRG) in
Major Diagnostic Category 5, diseases and disorders of the
circulatory system (as defined by the U.S. Centers for
Medicare and Medicaid Services).
Prolonged length of stay was defined as a length of stay
greater than the 75th percentile, > 6 days in our study. Ele-
vated pharmacy cost was defined as a pharmacy cost
greater than the 75th percentile, > $938 in our study. Pre-
vious studies in the area of clinical epidemiology have
used the 75th percentile to dichotomize a continuous var-
iable [14,15].
The SAS System Release 8.02 (SAS Institute, Inc., Cary,
North Carolina) was used to perform logistic regression.
Crude and adjusted odds ratios (OR) for the four out-
comes were calculated along with 95% confidence inter-
vals (CI) using PROC GENMOD. Two methods were used
to control for confounding by disease severity: Multivari-
ate modeling, and stratification with multivariate mode-
ling. Initially, the nesiritide odds ratio was adjusted for the
following two disease severity measures (one at a time)
using a logistic regression model: All Patient Refined-
Diagnosis Related Group (APR-DRG) severity of illness
score, and the APR-DRG risk of mortality score [16]. These
two patient classification systems incorporate a variety of
demographic and clinical information including age, sex,
diagnoses, and procedures. The final models included one
of the two severity scores, a race/ethnicity variable (White,
Black, Hispanic, and Other), a variable identifying low
economic status (yes/no), and the following nine medica-
tions: angiotensin converting enzyme inhibitors, angi-
otensin II receptor antagonists, digoxin, diuretics,BMC Cardiovascular Disorders 2007, 7:37 http://www.biomedcentral.com/1471-2261/7/37
Page 3 of 7
(page number not for citation purposes)
dobutamine, dopamine, beta-blockers, intravenous nitro-
glycerin, and milrinone. Multicollinearity was not
detected in these final/full models.
In the second approach, odds ratios for hospital mortality
were stratified by the two different severity measures: APR-
DRG severity of illness score, and the APR-DRG risk of
mortality score. Analyses of the remaining three outcomes
were stratified by the APR-DRG severity of illness score. In
each of the strata the OR was adjusted for the receipt of the
following medications: angiotensin converting enzyme
inhibitors, angiotensin II receptor antagonists, digoxin,
diuretics, dobutamine, dopamine, beta-blockers, intrave-
nous nitroglycerin, and milrinone.
Both of the APR-DRG measures are ordinal variables rang-
ing from 1 to 4. Due to the small number of deaths and
episodes of prolonged length of stay among patients clas-
sified as APR-DRG severity level 1 or APR-DRG risk of
mortality level 1, several of the logistic regression models
in the stratified analysis failed to converge. To counteract
this problem we collapsed levels 1 and 2 into one category
for both APR-DRG indices. We did not alter the APR-DRG
indices for our initial multivariate analyses.
Repeated Measurements
The inclusion of multiple records for certain patients
required a method to account for the correlated nature of
the data. Generalized estimating equations (GEE) were
used to address this issue [17]. GEE was used to calculate
robust standard errors leading to appropriate 95% confi-
dence intervals for the population odds ratios. An
exchangeable correlation structure was specified [18].
Secondary Statistical Analysis
To ensure a more homogenous study sample only unique
patients were included in a secondary analysis. To clarify,
the primary analysis included a group of patients who
were admitted multiple times for CHF during the study
period. It is likely that these individuals were sicker than
CHF patients who were only admitted once during the
three-years of observation and therefore more likely to
receive nesiritide. To minimize the risk of confounding by
disease severity a secondary analysis was performed in
which only the record of the initial episode of care was
retained if the patient had two or more admissions for
CHF. There were 18,195 patients who fell into this cate-
gory after deleting records with missing values.
Crude and adjusted ORs associated with inpatient nesir-
itide treatment were calculated using PROC LOGISTIC in
SAS. The following four outcomes were studied: hospital
mortality, prolonged length of stay (defined below), ele-
vated pharmacy cost (defined below), and readmission to
an AHS hospital within 31 days for a cardiac/circulatory
system disorder other than CHF. Prolonged length of stay
was defined as a length of stay greater than the 75th per-
centile, > 6 days in our study. Elevated pharmacy cost was
defined as a pharmacy cost greater than the 75th percen-
tile, > $928 in our study.
The study protocol was approved by the Committee for
the Protection of Human Subjects at The University of
Texas Health Science Center at Houston.
Results
Approximately 11% of the CHF cohort (2692 patients)
received nesiritide during their hospital stay (Table 1).
Table 1 indicates that the patients who received nesiritide
were more severely ill than the patients who did not
receive nesiritide. Overall, 805 of the 25,330 patients
expired in the hospital (Table 1). The distribution of the
deaths was as follows: 126 patients who received nesir-
itide, and 679 patients who did not receive nesiritide
(Table 1). The crude hospital mortality rate among
patients who received nesiritide was 57% higher than the
hospital mortality rate among patients who did not
receive nesiritide: 4.7% versus 3.0% (Relative risk = 1.57)
(Figure 1, and Table 1).
Nesiritide treatment was associated with a 59% higher
odds of hospital mortality (crude OR = 1.59, 95% CI:
1.31–1.93) (Table 2). The crude relative risk for hospital
death (1.57) and the crude odds ratio for hospital death
(1.59) are similar indicating that the outcome of hospital
mortality was not a common event. Adjusting for either of
the APR-DRG measures attenuated the nesiritide ORs for
hospital mortality and resulted in ORs that were not sta-
tistically significant. Crude and adjusted ORs revealed that
Unadjusted rates of four outcomes by nesiritide status Figure 1
Unadjusted rates of four outcomes by nesiritide status.
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treatment with nesiritide was associated with higher odds
of prolonged length of stay and elevated pharmacy cost.
Stratifying by APR-DRG severity of illness did not reveal
any associations between nesiritide and hospital mortality
and nesiritide and readmission within 31 days for a car-
diac condition (Table 3). Increased odds of prolonged
length of stay and elevated pharmacy cost were linked to
nesiritide treatment (Table 3).
A large number of patients were classified as having an
APR-DRG risk of mortality of 1 or 2 (Table 4). After strat-
ifying by the APR-DRG risk of mortality score, nesiritide
neither significantly increased nor decreased the odds of
mortality.
In a secondary analysis the sample was restricted to only
one record per patient. If the patient was admitted more
than once for CHF during the three-year study period then
only the initial episode of care was retained. Unadjusted
and adjusted ORs for the four outcomes of interest are
shown in Table 5 for these 18,195 unique patients. The
unadjusted hospital mortality OR (Table 5) was slightly
attenuated compared to its counterpart in Table 2 but was
still statistically significant. The four ORs for readmission
within 31 days for a cardiac condition/disorder of the cir-
culatory system other than CHF (Table 5) were higher
than the readmission ORs in Table 2 and were significant
at the 0.05-level unlike the readmission ORs in Table 2.
Discussion
Several recent events caused our health system to look at
our own internal data regarding outcomes when nesiritide
is used to treat patients with ADHF: 1. Several recent stud-
ies suggesting a negative impact of nesiritide on mortality
and renal function [10,11], 2. A major academic medical
center expressing concerns regarding nesiritide use [12], 3.
A federal subpoena issued regarding marketing strategies
for this medication [19], 4. The need for a national panel
of cardiology and heart failure experts to re-review data
regarding outcomes of patient's treated with nesiritide
[13], and 5. Our own corporate data suggesting significant
increases in the use of nesiritide.
Our post-marketing surveillance study found that after
accounting for various clinical and demographic varia-
bles, there was no relationship between nesiritide and
hospital mortality. Our preliminary analysis used a
slightly different set of potential confounders and found
that treatment with nesiritide was associated with a 26%
increase in the odds of hospital mortality (Adjusted inci-
dence odds ratio = 1.26) [20,21]. Even though this result
was statistically significant (p = 0.03) it was barely so as
evidenced by a 95% CI that almost contained the null
value of one: 1.02–1.57. In a meta-analysis of clinical trial
data, Sackner-Bernstein et al. [10] found a risk ratio of
death within 30 days of 1.74 for patients randomized to
nesiritide (95% CI: 0.97–3.12) and a hazard ratio after
adjusting for study of 1.80 (95% CI: 0.98–3.31). A revised
study by Aaronson and Sackner-Bernstein revealed
adjusted relative risks of approximately 1.9 for mortality
within 30 days of treatment for nesiritide versus control
therapy [22]. These relative risks were statistically signifi-
cant, but, nonetheless, the authors caution that their stud-
ies were not designed to conclusively determine if
nesiritide is associated with the risk of death [22].
Table 1: Demographic and Clinical Characteristics of 25,330 
Patients Hospitalized for CHF
Variable Received 
nesiritide 
(n = 2692)
Did not receive 
nesiritide 
(n = 22,638)
Number (%) Number (%)
Demographic variables*
Race/Ethnicity
Black 292 (10.9) 2438 (10.8)
Hispanic 266 (9.9) 1570 (6.9)
White 2125 (78.9) 18,512 (81.8)
Other race 9 (0.3) 118 (0.5)
Low economic status 118 (4.4) 960 (4.2)
Medications
ACE inhibitors 1558 (57.9) 12,173 (53.8)
Angiotensin II receptor antagonists 574 (21.3) 3478 (15.4)
Diuretics 2658 (98.7) 21,650 (95.6)
Digoxin 1320 (49.0) 8925 (39.4)
Beta blockers 2114 (78.5) 13,849 (61.2)
Dobutamine 341 (12.7) 1131 (5.0)
Dopamine 315 (11.7) 1185 (5.2)
IV nitroglycerin 313 (11.6) 1762 (7.8)
Milrinone 150 (5.6) 272 (1.2)
Severity measures
APR-DRG Severity of Illness
1 or 2 1343 (49.9) 14,653 (64.7)
3 1077 (40.0) 6979 (30.8)
4 272 (10.1) 1006 (4.4)
APR-DRG Risk of Mortality
1 or 2 1618 (60.1) 16,716 (73.8)
3 781 (29.0) 4661 (20.6)
4 293 (10.9) 1261 (5.6)
Outcomes
Hospital mortality 126 (4.7) 679 (3.0)
Prolonged length of stay 1088 (40.4) 4973 (22.0)
Elevated pharmacy cost 1688 (62.7) 4640 (20.5)
Readmission within 31 days for 
cardiac condition
340 (12.6) 2318 (10.2)
* Median age of patients who received nesiritide (range) = 74 years 
(20–100 years), median age of patients who did not receive nesiritide 
(range) = 76 years (18–105 years)BMC Cardiovascular Disorders 2007, 7:37 http://www.biomedcentral.com/1471-2261/7/37
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Nesiritide was associated with a prolonged length of stay
in the hospital and increased pharmacy cost in our inves-
tigation. The cost data are disturbing, although not com-
pletely surprising. Since January 2003 nesiritide has
ranked among the top 10 medications contributing to
overall AHS corporate medication costs. For 2005 year to
date, it ranks as the third most expensive medication
across our corporation despite being used in only 11% of
our CHF admissions. However, the magnitude of the ele-
vated pharmacy costs (adjusted odds ratios of greater than
5 for the nesiritide treated group) was unexpected. The
obvious question at this point is whether or not this sig-
nificantly increased cost is warranted, particularly given
the increased length of stay.
We believe this retrospective review of data from geo-
graphically dispersed hospitals in our health system is
probably representative of how nesiritide is used across
the USA in community hospitals as opposed to academic
medical centers where research trials are typically con-
ducted. Even though our data are not from a clinical trial
or an industry-sponsored registry our dataset was similar
to the ADHERE Registry with respect to the use of nesir-
itide: 11% of our patients were treated with nesiritide
while 12% of the patients in the ADHERE Registry were
on nesiritide [23]. Our use of a non-industry-sponsored
dataset can be viewed as an advantage since industry-
sponsored patient registries may suffer from sampling
bias. The three-year period for this observational study
allowed us to include over 25,000 patient encounters
including over 2,600 patients that received nesiritide. In
comparison, the VMAC trial enrolled 489 patients, 204 of
whom received nesiritide [24].
A retrospective study has several limitations. Our data set
did not allow us to determine when or where nesiritide
therapy began and for how long the infusion was contin-
ued. We were also unable to obtain salient clinical param-
eters such as etiology of the heart failure, left ventricular
ejection fraction on admission, serum brain natriuretic
peptide levels, pulmonary capillary wedge pressure read-
ings, or other estimates of the degree of volume overload.
Such variables may have increased the sensitivity of our
severity adjustments. Some authors have suggested reserv-
ing nesiritide for only the most seriously ill patients. How-
ever, our data, when stratified by severity level (Tables 3
Table 3: Odds Ratios* for Four Outcomes Stratified by APR-DRG Severity of Illness: Nesiritide compared to No Nesiritide
APR-DRG severity of 
illness score
Hospital mortality OR† 
(95% CI‡)
Prolonged length of stay 
OR (95% CI)
Elevated pharmacy cost 
OR (95% CI)
Readmission within 31 days 
for cardiac condition OR 
(95% CI)
1 or 2 (n = 15,996) 1.22 (0.70–2.12) 1.66 (1.43–1.93) 6.45 (5.67–7.33) 1.09 (0.79–1.50)
3 (n = 8056) 0.89 (0.62–1.28) 1.70 (1.49–1.95) 4.63 (3.98–5.39) 1.19 (0.94–1.51)
4 (n = 1278) 1.12 (0.79–1.60) 1.62 (1.15–2.28) 4.44 (2.84–6.95) (model failed)
Total (n = 25,330)
* Adjusted for the nine medications listed in Table 1
† OR = odds ratio
‡ CI = confidence interval
Table 2: Crude and Adjusted Odds Ratios for Four Outcomes: Nesiritide compared to No Nesiritide (n = 25,330)
Outcome
Type of odds ratio Hospital mortality 
OR† (95% CI‡)
Prolonged length of 
stay OR (95% CI)
Elevated pharmacy 
cost OR (95% CI)
Readmission within 31 days for 
cardiac condition OR (95% CI)
Unadjusted 1.59 (1.31–1.93) 2.41 (2.21–2.62) 6.24 (5.72–6.80) 1.11 (0.89–1.39)
Adjusted for 9 medications* 1.26 (1.00–1.58) 1.89 (1.72–2.06) 5.35 (4.88–5.86) 1.14 (0.90–1.44)
Adjusted for APR-DRG severity of illness score 1.04 (0.85–1.27) 1.99 (1.82–2.19) 6.24 (5.67–6.87) 1.14 (0.91–1.42)
Adjusted for 9 medications, APR-DRG severity of 
illness score, race, and low economic status
1.07 (0.85–1.35) 1.66 (1.51–1.83) 5.45 (4.93–6.01) 1.15 (0.91–1.45)
Adjusted for APR-DRG risk of mortality score 1.03 (0.84–1.27) N/A N/A N/A
Adjusted for APR-DRG risk of mortality score, 9 
medications, race, and low economic status
1.06 (0.84–1.35) N/A N/A N/A
* Listed in Table 1
† OR = odds ratio
‡ CI = confidence intervalBMC Cardiovascular Disorders 2007, 7:37 http://www.biomedcentral.com/1471-2261/7/37
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and 4), would suggest that the sickest patients did not
benefit more with nesiritide as anticipated. Also, our data-
set was unable to determine whether or not the addition
of nesiritide improved diuresis.
Our study was not a randomized controlled trial; how-
ever, it would have been challenging to enroll as many
patients as we had (over 18,000) in a clinical trial. Fur-
thermore, randomized clinical trials offer insights into the
efficacy of an intervention but not necessarily the effec-
tiveness of an intervention. In other words, clinical trials
are conducted under somewhat artificial conditions while
observational studies take place in the "real" world.
The principal limitation of this study is the observational
design and the fact that it is known that sicker patients
receive nesiritide. The study design cannot overcome
unmeasured confounding or a bias from the inclusion of
a select group of severe patients who may have been chan-
neled to the therapy under investigation. Therefore the
results are ultimately hypothesis generating. However, the
results of this study provide clear impetus for randomized
controlled trials to define the role of nesiritide in the treat-
ment of heart failure.
If nesiritide is a useful agent in the treatment of ADHF, the
conditions under which it has proven utility must be doc-
umented and defined. While lowering pulmonary capil-
lary wedge pressure and improving dyspnea are
advantageous in ADHF, they alone do not warrant the
increased cost of nesiritide use. This is particularly true
when other outcome measures such as length of stay in
our study and survival and renal function in other studies
[10,11] have shown disturbing trends.
We add our voice to those others who seek data from ran-
domized, controlled clinical trials as to the utility for
nesiritide in the treatment of ADHF [13,25].
Conclusion
In this observational study, nesiritide therapy was associ-
ated with increased length of stay and pharmacy cost, but
not hospital mortality. Randomized trials are urgently
needed to better define the efficacy, if any, of nesiritide in
the treatment of decompensated heart failure.
List of Abbreviations
ADHF = acute decompensated heart failure
AHS = Adventist Health System
APR-DRG = All Patient Refined-Diagnosis Related Group
Table 5: Crude and Adjusted Odds Ratios for Four Outcomes in a Sample of CHF Patients with Only One Record per Patient*: 
Nesiritide compared to No Nesiritide (n = 18,195 unique patients)
Outcome
Type of odds ratio Hospital mortality 
OR† (95% CI‡)
Prolonged length of 
stay OR (95% CI)
Elevated pharmacy 
cost OR (95% CI)
Readmission within 31 days for cardiac 
condition other than CHF OR (95% CI)
Unadjusted 1.48 (1.14–1.93) 2.51 (2.26–2.79) 6.82 (6.12–7.61) 1.25 (1.05–1.49)
Adjusted for 9 medications** 1.23 (0.91–1.65) 1.97 (1.76–2.20) 5.78 (5.15–6.48) 1.25 (1.05–1.49)
Adjusted for APR-DRG severity of illness 
score
0.87 (0.66–1.15) 1.97 (1.76–2.22) 6.60 (5.85–7.43) 1.26 (1.06–1.50)
Adjusted for 9 medications, APR-DRG 
severity of illness score, race, and low 
economic status
0.98 (0.72–1.34) 1.65 (1.46–1.86) 5.66 (5.01–6.40) 1.25 (1.04–1.49)
Adjusted for APR-DRG risk of mortality 
score
0.89 (0.68–1.18) N/A N/A N/A
Adjusted for APR-DRG risk of mortality 
score, 9 medications, race, and low 
economic status
1.01 (0.74–1.37) N/A N/A N/A
* This sample excluded the subsequent records of patients who were admitted multiple times for CHF during the study period
** Listed in Table 1
† OR = odds ratio
‡ CI = confidence interval
Table 4: Odds Ratios* for Hospital Mortality Stratifiedby APR-
DRG Risk of Mortality: Nesiritide compared to No Nesiritide
APR-DRG risk of mortality score Odds ratio 
(95% confidence interval)
1 or 2 (n = 18,334) 1.20 (0.69–2.10)
3 (n = 5442) 0.87 (0.59–1.27)
4 (n = 1554) 1.18 (0.85–1.64)
Total (n = 25,330)
* Adjusted for the nine medications listed in Table 1BMC Cardiovascular Disorders 2007, 7:37 http://www.biomedcentral.com/1471-2261/7/37
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CHF = congestive heart failure
CI = confidence interval
OR = odds ratio
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